reverse-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-21. Anything still debated is marked as such rather than presented as settled.
Reconstitution concentration is chosen from the mass of peptide and the volume of solvent added. Researchers often prepare a concentrated stock and then divide it into single-use aliquots to reduce freeze-thaw cycling. The actual peptide content may differ from label mass because of counterions, water, or impurities. For that reason, quantitative work may require independent measurement such as amino acid analysis or ultraviolet absorbance. Records of solvent, volume, date, and lot help trace later observations.
Lyophilized peptides are supplied as dry powders or porous cakes that remain stable during shipment and short-term storage. Reconstitution is the laboratory step of adding a suitable solvent so the solid dissolves into a liquid stock. The dried state limits hydrolysis and microbial growth, but it does not remove all residual water or salts. Sequence, counterion, and manufacturing method influence how quickly and completely a peptide enters solution. Researchers treat reconstitution as a practical starting point for later dilution, analysis, or assay work.
The concentration of a reconstituted peptide is calculated from the mass of peptide powder and the volume of solvent added. This calculation assumes the powder contains only peptide, but many preparations include counterions, water, or salts. Analytical methods such as ultraviolet absorbance or amino acid analysis can estimate actual peptide content. The relationship between nominal and actual concentration is an area where measurements matter. Open questions remain about how aggregation changes the effective concentration in solution.
Peptide reconstitution is the process of dissolving a lyophilized peptide in a liquid to form a solution for later use. Lyophilization removes water under vacuum, leaving a dry powder or porous cake. Reconstitution reintroduces solvent so the peptide molecules return to a dissolved state. The solvent may be purified water, a buffer, or a mixture containing an organic co-solvent. The choice depends on the peptide sequence, its charge, and its hydrophobicity.
| Property | Value | Notes |
|---|---|---|
| Appearance (lyophilized) | White to off-white powder or cake | Depends on peptide sequence, counterion, and manufacturing process |
| Appearance (reconstituted) | Clear to slightly hazy solution | Visible particles may indicate incomplete dissolution or aggregation |
| Solubility class | Aqueous or organic-dependent | Hydrophilic peptides often dissolve in water; hydrophobic peptides may require acetonitrile or dimethyl sulfoxide |
| Typical storage temperature (lyophilized) | -20 °C or lower | Desiccated, protected from light, and allowed to equilibrate before opening |
| Typical analytical method | Reverse-phase HPLC or LC-MS | Used to confirm identity, purity, and concentration after dissolution |
Buffer components and ionic strength affect how a peptide dissolves and remains in solution. Some sequences require a defined pH range to avoid precipitation or aggregation, while others tolerate pure water. The optimal conditions are often determined empirically because solubility cannot be predicted reliably from sequence alone. Even when a peptide dissolves, the resulting solution may contain aggregates that are not visible to the eye. Analytical methods such as reversed-phase high-performance liquid chromatography and mass spectrometry are used to confirm identity and purity after reconstitution.
Peptide reconstitution is the process of dissolving a dried peptide preparation in a liquid solvent to form a solution. Many peptides are supplied as lyophilized powders because removing water improves stability during shipping and storage. The dried material may appear as a cake, flake, or loose powder depending on the manufacturing and drying method. Reconstitution restores the peptide to a liquid state so that it can be further diluted, analyzed, or handled in laboratory workflows. The term is distinct from dilution, which lowers concentration after a solution already exists.
The choice of solvent depends on the peptide's sequence, charge, and solubility profile. Water is common for hydrophilic peptides, while aqueous mixtures containing acetonitrile, methanol, or a small amount of acid may be needed for hydrophobic or basic sequences. Adding the liquid to the powder, rather than the reverse, can reduce clumping and improve wetting. Gentle mixing or brief vortexing may help, but vigorous agitation can create foam and shear sensitive structures. Complete dissolution is judged by a clear solution with no visible particles.
Solvent choice depends on the peptide's sequence, charge, and solubility profile. Sterile water is common for freely soluble peptides, while aqueous buffers or dilute acid or base may be needed for others. Some sequences contain hydrophobic regions that resist water alone and require a small amount of organic co-solvent. The solvent's pH can affect charge state, aggregation, and stability. Because peptides vary widely, no single universal reconstitution liquid exists, and suppliers often provide a recommended solvent based on testing of a specific lot or sequence.
After a solvent is added, the vial is typically swirled or gently inverted rather than shaken vigorously. Shaking can introduce air and shear forces that promote foaming or aggregation, especially for longer peptides. Dissolution may take several minutes, and the solution should become clear unless the peptide is intentionally in suspension. Concentration is calculated from the mass of peptide stated on the vial label divided by the total liquid volume. If the dried peptide contains salts or counterions, the actual peptide content may be lower than the nominal mass.
Reconstitution is the process of adding a liquid to a lyophilized peptide so that the dried material dissolves into solution. Lyophilization removes water from a frozen peptide preparation under reduced pressure, leaving a porous solid or powder. The dried form often has greater long-term stability than a liquid because hydrolysis and oxidation are slowed. In laboratory work, reconstitution is usually the first step before dilution, analysis, or further experiments. The result is a stock solution whose concentration depends on the volume of solvent added and the amount of peptide in the vial.
Neurotransmitter receptors and receptor ionophores. Nicotinic, imidazoline I1 and I2, α2-adrenergic, glutamate NMDAr, and serotonin 5-HT2A and 5HT-3 receptors. Ion channels. Including: ATP-sensitive K+ channels, voltage-gated Ca2+ channels, and acid-sensing ion channels (ASICs). Membrane transporters. Agmatine specific-selective uptake sites, organic cation transporters (mostly OCT2 subtype), extraneuronal monoamine transporters (ENT), polyamine transporters, and mitochondrial agmatine specific-selective transport system. Nitric oxide (NO) synthesis modulation. Both differential inhibition and activation of NO synthase (NOS) isoforms is reported. Polyamine metabolism. Agmatine is a precursor for polyamine synthesis, competitive inhibitor of polyamine transport, inducer of spermidine/spermine acetyltransferase (SSAT), and inducer of antizyme. Protein ADP-ribosylation. Inhibition of protein arginine ADP-ribosylation. Matrix metalloproteases (MMPs). Indirect down-regulation of the enzymes MMP 2 and 9. Advanced glycation end product (AGE) formation. Direct blockade of AGEs formation. NADPH oxidase. Activation of the enzyme leading to H2O2 production.
== Current Scenario of bsAb drugs == Several bsAb drugs have been approved by the US FDA / EMA and over 180 are currently in clinical trials. The first bispecific antibody to gain regulatory approval, blinatumomab, targets CD19 on B cells and CD3 on T cells, leading to the activation of T cells and the destruction of B cells. Additional bispecific antibody drugs have since been approved by the US FDA: emicizumab, amivantamab, tebentafusp, faricimab, teclistamab, mosunetuzumab, epcoritamab, glofitamab. Among the bsAb programs currently under development, the combination of CD3 and tumor surface targets are the most popular targets pairs. Other popular targets are HER2, PD-1, PD-L1, EGFR, CTLA-4, etc., which as well as immune targets of PD-1, PD-L1, BCMA, CD47, CTLA-4, LAG-3, 4 -1BB. Additionally, with the approval of the several new bsAb since 2022, and new mechanisms for improving efficacy like development of hetero-dimer bispecific molecules, several additional possibilities of target pairs have emerged.
=== Fragment-based === The most common of these uses a group contribution method and is termed cLogP. It has been shown that the log P of a compound can be determined by the sum of its non-overlapping molecular fragments (defined as one or more atoms covalently bound to each other within the molecule). Fragmentary log P values have been determined in a statistical method analogous to the atomic methods (least-squares fitting to a training set). In addition, Hammett-type corrections are included to account of electronic and steric effects. This method in general gives better results than atomic-based methods, but cannot be used to predict partition coefficients for molecules containing unusual functional groups for which the method has not yet been parameterized (most likely because of the lack of experimental data for molecules containing such functional groups).
Removal of a proton from an aliphatic –OH group is difficult to achieve in aqueous solution because the energy required for this process is rather large. Thus, ionization of aliphatic –OH groups occurs in aqueous solution only in special circumstances. One such circumstance is found with compounds containing the H2N–C–C–OH substructure. For example, compounds containing the 2-aminoethanol substructure can form metal–chelate complexes with the deprotonated form, H2N–C–C–O−. The chelate effect supplies the extra energy needed to break the O–H bond. An important example occurs with the molecule tris. This molecule should be used with caution as a buffering agent as it will form chelate complexes with ions such as Fe3+ and Cu2+.
==== Corona treatment ==== Corona treatment is a surface modification method using a low temperature corona discharge to increase the surface energy of a material, often polymers and natural fibers. Most commonly, a thin polymer sheet is rolled through an array of high-voltage electrodes, using the plasma created to functionalize the surface. The limited penetration depth of such treatment provides vastly improved adhesion while preserving bulk mechanical properties. Commercially, corona treatment has been used widely for improved dye adhesion before printing text and images on plastic packaging materials. The hazardous nature of remnant ozone after corona treatment stipulates careful filtration and ventilation during processing, restricting its implementation to applications with strict catalytic filtered systems. This limitation prevents widespread use within open-line manufacturing processes Several factors influence the efficiency of the flame treatment such as air-to-gas ratio, thermal output, surface distance, and oxidation zone dwell time. Upon conception of the process, a corona treatment immediately followed film extrusions, but the development of careful transportation techniques allows treatment at an optimized location. Conversely, in-line corona treatments have been implemented into full-scale production lines such as those in the newspaper industry. These in-line solutions are developed to counteract the decrease in wetting characteristics caused by excessive solvent use.
Sources: en.wikipedia.org
Histology image: 02003loa – Histology Learning System at Boston University – "Cartilage and Bone and Bone Histogenesis: cells of* Histology image: 02705loa – Histology Learning System at Boston University – "Cartilage and Bone and Bone Histogenesis: compact bone"* =D Histology at ou.edu
==== Dementia ==== Several studies have drawn an association between long-term benzodiazepine use and neurodegenerative disease, particularly Alzheimer's disease. It has been determined that long-term use of benzodiazepines is associated with increased dementia risk, even after controlling for protopathic bias. In contrast, a clinical study using florbetapir PET-CT and MRI to compute beta-amyloid load and hippocampal volume, respectively, found benzodiazepines to be associated with decreased beta-amyloid load and reduced hippocampal atrophy in a cohort of older nondemented adults with isolated/light cognitive impairments. Unlike previous imaging studies limited to MRI techniques, the utilization of a dual PET CT scanner to track the binding of the radioligand florbetapir to beta-amyloid provides stronger neuroimaging data with respect to alzheimer's related pathophysiology. Indeed, Avid's florbetapir PET technique has received FDA approval for diagnosing alzheimer's disease. Drug Approval Package Archived 10 June 2025 at the Wayback Machine However, there is still no causal evidence regarding how benzodiazepines affect the risk of alzheimer's disease or dementia.
During the early phase of the COVID-19 pandemic, Duterte downplayed the severity of the outbreak and urged the public to avoid anti-Chinese sentiment. In a February 2020 press briefing, he assured citizens that "everything is well" and stated that the public should refrain from discriminating against Chinese nationals. The first reported COVID-19 case in the Philippines was on January 30, 2020, prompting Duterte to issue bans on the entry of Chinese nationals from China and calling for calm. Duterte changed his tune in March, during which he placed the Philippines under a State of National Calamity and ordered a lockdown in Luzon. His administration opted to use what it described as "draconian measures" to control the contagion, and Duterte employed the military and police to enforce the public's strict adherence to quarantine and health protocols. As countries were scrambling in securing COVID-19 vaccines for their own citizens, Duterte called for patience amid criticism. To expedite vaccine procurement, Duterte rejected creating a committee and designated Carlito Galvez Jr. as "vaccine czar", who had the gargantuan task of acquiring vaccines from other countries. Additionally, Duterte personally requested vaccines from world leaders, notably Chinese president Xi Jinping and Russian President Vladimir Putin. China and Russia responded favorably, and the Duterte administration started its vaccination program on March 1, 2021, a day after receiving 600,000 CoronaVac vaccines sent by the Chinese government.
In the United States, a group of companies including OpenAI, Alphabet, and Meta signed a voluntary agreement with the Biden administration in July 2023 to watermark AI-generated content. In October 2023, Executive Order 14110 applied the Defense Production Act to require all US companies to report information to the federal government when training certain high-impact AI models. In the European Union (EU), the Artificial Intelligence Act includes requirements to disclose copyrighted material used to train generative AI systems, and to label any AI-generated output as such. In China, the Interim Measures for the Management of Generative AI Services introduced by the Cyberspace Administration of China regulates any public-facing generative AI. It includes requirements to watermark generated images or videos, regulations on training data and label quality, restrictions on personal data collection, and a guideline that generative AI services must "adhere to socialist core values". In 2021, UNESCO adopted the Recommendation on the Ethics of Artificial Intelligence, the first global standard-setting instrument on AI. It provides guidance to member states on issues including human rights, fairness, transparency, data governance, and environmental sustainability. The Group of Seven (G7) launched the Hiroshima AI Process in 2023, which produced international guiding principles and a voluntary code of conduct for developers of advanced AI systems.
Citicoline (INN), also known as cytidine diphosphate-choline (CDP-choline) or cytidine 5'-diphosphocholine is an intermediate in the generation of phosphatidylcholine from choline, a common biochemical process in cell membranes. Citicoline is naturally occurring in the cells of human and animal tissue, in particular the organs.
Sources: en.wikipedia.org
The solvent depends on peptide sequence and application. Water or aqueous buffer works for many hydrophilic peptides, while hydrophobic peptides may require a water-miscible organic solvent. The chosen solvent must be compatible with the assay or analytical instrument.
No. Some material may remain as insoluble particles, adsorb to surfaces, or degrade during handling. Recovery can be checked by analytical methods such as chromatography or mass spectrometry.
Aliquoting limits repeated freezing and thawing, which can cause aggregation or loss. Single-use portions also reduce contamination risk. Storage conditions depend on peptide stability.
Lyophilization removes water to produce a dry peptide preparation. Reconstitution adds a solvent back to that preparation to create a liquid solution. The two processes are complementary steps in the lifecycle of many peptide products.